Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe-Reference-Cited by-同舟云学术

Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe

Published:2022-03 Issue:2 Volume:36 Page:217-229
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Barcina Lacosta Teresa^ORCID,Vulto Arnold G.^ORCID,Turcu-Stiolica Adina^ORCID,Huys Isabelle^ORCID,Simoens Steven^ORCID

Funder

KU Leuven MABEL Fund

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s40259-022-00523-z.pdf

Reference59 articles.

1. European Medicines Agency (EMA). Biosimilars in the EU. Information guide for healthcare professionals. 2019.

2. European Medicines Agency (EMA). Medicines for Human Use Under Evaluation. 2021. https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation. Accessed 12 July 2021.

3. European Medicines Agency (EMA). CHMP: Agendas, minutes and highlights. 2021. https://www.ema.europa.eu/en/committees/chmp/chmp-agendas-minutes-highlights. Accessed 12 July 2021.

4. European Medicines Agency (EMA). Search engine EMA. Centrally authorised biosimilar medicines 2021. https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_medicine/field_ema_med_status/authorised-36/ema_medicine_types/field_ema_med_biosimilar/search_api_aggregation_ema_medicine_types/field_ema_med_biosimilar. Accessed 12 July 2021.

5. IQVIA. The Impact of Biosimilar Competition in Europe. 2020.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective;Journal of Medical Economics;2024-07-23

2. Charting the Etanercept Journey: Tracing Cost Dynamics in Poland’s Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly;BioDrugs;2024-06-11

3. Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market;Expert Opinion on Biological Therapy;2024-06-06

4. Learnings from cross-border biosimilar pricing policies in Europe;Expert Review of Pharmacoeconomics & Outcomes Research;2024-03-26

5. Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review;Frontiers in Public Health;2024-02-28